Physician profile
Robert Kindel
NPI 1134120348
$4,956.93
in general payments reported to CMS, 2019-2025
28 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.88 · 2020: $211 · 2021: $394 · 2022: $628 · 2023: $917 · 2024: $1,142 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,640 · Education: $18.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,640.20 |
| Education | $18.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $830.10 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $545.30 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $470.97 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $409.91 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.97 | 2021-2025 | Xifaxan, Relistor |
| Ironwood Pharmaceuticals, INC | $249.05 | 2020-2025 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $243.24 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $212.78 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $204.64 | 2021-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $196.22 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $150.36 | 2024-2025 | |
| Gilead Sciences, INC. | $144.61 | 2022-2025 | |
| Pfizer INC. | $140.21 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $127.25 | 2021-2023 | |
| Lilly USA, LLC | $122.46 | 2024-2025 | Omvoh |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $84.58 | 2021-2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $76.39 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $60.71 | 2023-2024 | Dificid |
| Organon LLC | $56.13 | 2022-2025 | Renflexis, Hadlima |
| Daiichi Sankyo INC. | $55.60 | 2021-2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $55.26 | 2023-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $42.68 | 2020-2024 | |
| Ardelyx, INC. | $40.38 | 2025 | Ibsrela |
| Novo Nordisk INC | $40.28 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $33.04 | 2022-2023 | Sutab |
| Aimmune Therapeutics, INC. | $28.06 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $18.05 | 2023 | Yuflyma |
| Allergan, INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kindel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.